Black Rock Inc. Age X Therapeutics, Inc. Transaction History

Black Rock Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.33 - $0.74 $2,522 - $5,657	-7,645 Reduced 5.79%	124,301 $47,000
Q3 2023 Nov 13, 2023	BUY	$0.67 - $0.85 $68 - $86	102 Added 0.08%	131,946 $89,000
Q2 2023 Aug 11, 2023	BUY	$0.45 - $0.89 $19 - $39	44 Added 0.03%	131,844 $117,000
Q1 2023 May 12, 2023	SELL	$0.56 - $0.8 $81 - $116	-145 Reduced 0.11%	131,800 $86,000
Q4 2022 Feb 13, 2023	SELL	$0.54 - $0.68 $99 - $125	-185 Reduced 0.14%	131,945 $72,000

Q3 2022 Nov 14, 2022	SELL	$0.55 - $0.74 $3,980 - $5,355	-7,237 Reduced 5.19%	132,130 $74,000
Q2 2022 Aug 12, 2022	SELL	$0.57 - $1.0 $30,821 - $54,073	-54,073 Reduced 27.95%	139,367 $80,000
Q1 2022 May 12, 2022	SELL	$0.65 - $1.2 $1,889 - $3,488	-2,907 Reduced 1.48%	193,440 $165,000
Q4 2021 Feb 10, 2022	BUY	$0.53 - $1.09 $1,054 - $2,168	1,989 Added 1.02%	196,347 $214,000
Q3 2021 Nov 09, 2021	SELL	$0.93 - $1.54 $960 - $1,590	-1,033 Reduced 0.53%	194,358 $183,000
Q2 2021 Aug 11, 2021	BUY	$1.14 - $1.77 $222,745 - $345,842	195,391 New	195,391 $303,000

127K

Ticker AGE
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,945,100
Description
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-rel...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.